<DOC>
	<DOC>NCT01939548</DOC>
	<brief_summary>This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 from baseline compared to placebo.</brief_summary>
	<brief_title>An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment Evidence of stable schizophrenia symptomatology greater than or equal to 3 months. Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications. History of seizures or of a condition with risk of seizures. Subjects with schizophrenia that have not responded at all to current treatment. Pregnant or nursing females, and females of child bearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>PF-02545920</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>outpatient</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>suboptimal response</keyword>
</DOC>